flow semaglutide clinical trial 🔴Cardiovascular outcomes with by severity of chronic kidney disease in type 2 diabetes: the trial⤵️ 🔹Semaglutide significantly reduced the risk of CV death/MI/stroke regardless of baseline CKD severity in participants Semaglutide versus placebo in individuals

W.FulcherG.EronduN.ShawW.et al

In the UK, both tirzepatide (Mounjaro) and semaglutide (Wegovy) for weight loss are currently administered via a once-weekly subcutaneous injection using a pre-filled pen.

For elderly people who easily forget to take their medication, this may be a new challenge

But some feedback also mentions common problems, like treatment discontinuation

Improper disposal of used pens and needles poses risks to family members, sanitation workers, and water systems

The metoclopramide black box warning for tardive dyskinesia: effect on clinical practice, adverse event reporting, and prescription drug lawsuits